Maravai Lifesciences Holdings (MRVI) Common Equity (2020 - 2026)

Maravai Lifesciences Holdings' Common Equity history runs 7 years deep, the most recent figure standing at $211.6 million for Q1 2026.

• In Q1 2026, Common Equity fell 60.1% year-over-year to $211.6 million; the TTM figure through Mar 2026 stood at $211.6 million (down 60.1% YoY), while the FY2025 annual figure was $372.7 million, down 35.43% from the prior year.
• Common Equity was $211.6 million for Q1 2026 at Maravai Lifesciences Holdings, down from $372.7 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $905.2 million in Q4 2022 to a low of $211.6 million in Q1 2026.
• Historically, Common Equity has averaged $671.2 million across 5 years, with a median of $772.5 million in 2024.
• The sharpest annual moves came in 2022 and 2026: Common Equity surged 206.0% in 2022, then tumbled 60.1% in 2026.
• A 5-year view of Common Equity shows it stood at $905.2 million in 2022, then dropped by 12.74% to $789.9 million in 2023, then slipped by 26.92% to $577.2 million in 2024, then sank by 35.43% to $372.7 million in 2025, then slumped by 43.24% to $211.6 million in 2026.
• The last three Common Equity figures came in at $211.6 million (Q1 2026), $372.7 million (Q4 2025), and $431.9 million (Q3 2025), per Business Quant data.